Shares of Organigram Holdings Inc. (TSE:OGI – Get Free Report) dropped 0.4% on Monday . The company traded as low as C$2.18 and last traded at C$2.26. Approximately 174,291 shares were traded during mid-day trading, a decline of 22% from the average daily volume of 223,412 shares. The stock had previously closed at C$2.27.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on OGI. Canaccord Genuity Group lowered their price target on Organigram from C$3.60 to C$3.15 and set a “speculative buy” rating for the company in a report on Monday, December 9th. ATB Capital lowered their target price on Organigram from C$5.25 to C$3.50 in a research note on Tuesday, December 17th.
Get Our Latest Stock Report on OGI
Organigram Stock Down 0.5 %
Insiders Place Their Bets
In other news, Senior Officer Paolo De Luca sold 12,014 shares of the firm’s stock in a transaction on Thursday, October 24th. The shares were sold at an average price of C$2.52, for a total transaction of C$30,275.28. Insiders own 31.32% of the company’s stock.
Organigram Company Profile
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O’ Buds, Monjour, Trailblazer, SHRED’ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Featured Stories
- Five stocks we like better than Organigram
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- How Do Stock Buybacks Affect Shareholders?
- Transportation Stocks Investing
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.